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Abstract
The long-term efficacy of corticosteroid treatment and timing of treatment initiation among 
Duchenne muscular dystrophy (DMD) patients is not well-understood. We used data from a 
longitudinal, population-based DMD surveillance program to examine associations between 
timing of treatment initiation (early childhood [before or at age 5 years], late childhood [after age 
5 years], and naïve [not treated]) and five clinical outcomes (age at loss of ambulation; ages at 
onset of cardiomyopathy, scoliosis, and first fracture; and pulmonary function). Hazard ratios 
(HRs) and 95% confidence intervals (CIs) were estimated using survival analysis. DMD patients 
who initiated corticosteroid treatment in early childhood had a higher risk of earlier onset 
cardiomyopathy compared to cases who initiated treatment in late childhood (HR = 2.0, 95% CI = 
[1.2, 3.4]) or treatment naïve patients (HR = 1.9, 95% CI = [1.1, 3.2]), and higher risk of suffering 
a fracture (HR = 2.3, 95% CI = [1.4, 3.7] and HR = 2.6, 95% CI = [1.6, 4.2], respectively). 
Patients with early childhood treatment had slightly decreased respiratory function compared with 
those with late childhood treatment. Ages at loss of ambulation or scoliosis diagnosis did not differ 
statistically among treatment groups. We caution that the results from our study are subject to 
several limitations, as they were based on data abstracted from medical records. Further 
investigations using improved reporting of disease onset and outcomes are warranted to obtain a 
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more definitive assessment of the association between the timing of corticosteroid treatment and 
disease severity.
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Fractures; Pulmonary function
1. Introduction
Duchenne muscular dystrophy (DMD) is an inherited childhood-onset dystrophinopathy 
characterized by mutations in the DMD gene that leads to progressive muscle weakness. 
Most individuals with DMD lose their ability to walk by age 13 years [1,2]. In 2010, the 
prevalence of DMD was estimated at approximately 1.4 per 10,000 males aged 5 to 9 years 
and 1.02 per 10,000 males aged 5 to 24 years in several U.S. sites [3]. Currently, individuals 
with DMD are expected to survive beyond their teen years, as pharmacological treatment 
and clinical advances in cardiac and respiratory care have extended survival of affected 
individuals into their early 30s [4,5].
Most pharmacological treatments for DMD are aimed at delaying its progression by 
delaying onset of specific morbidities and prolonging muscle strength. At present, 
corticosteroids and angiotensin-converting enzyme (ACE) inhibitors are the most commonly 
prescribed treatments that have been reported to modify disease progression in individuals 
with DMD. Corticosteroids have been observed to improve or maintain muscle strength 
resulting in prolonged independent ambulation [6–13], a delay in cardiomyopathy onset or 
preservation of cardiac function [14–18], and preservation of pulmonary function [6,19–22], 
compared to untreated or natural history DMD controls. Early treatment (in children aged 
9.5 to 13 years) with the ACE inhibitor, perindopril, has been observed to delay onset and 
progression of left ventricle dysfunction in individuals with DMD [23,24].
Despite the reported therapeutic effects of corticosteroids, the long-term benefits and risks 
associated with their use are unclear, and there are no generally accepted guidelines for the 
timing of treatment initiation [25–29]. A few studies have observed that corticosteroids 
initiated before age 5 years preserved respiratory function [30], prolonged ambulatory 
function [9], and contributed to remission of clinical symptoms [31,32] in individuals with 
DMD. These findings should be interpreted with caution because these studies lacked 
sufficient statistical power due to limited sample sizes (fewer than 5 patients) and lacked 
comparison groups of patients who began treatment at later ages or were untreated [9,30–
32]. Moreover, some of these studies had follow-up periods (five years or less) [31,32] that 
were too short to evaluate long-term functional outcomes. As a result, the long-term 
effectiveness of corticosteroid treatment by timing of initiation, particularly in early 
childhood, has not been well-studied. A large-scale study with an extended follow-up period 
and a control group of affected individuals without corticosteroid treatment is needed to 
examine the associations between timing of treatment initiation and clinical outcomes in 
DMD. To address this need, we examined associations between corticosteroid treatment and 
timing of treatment initiation and five clinical outcomes – age at loss of ambulation; ages at 
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onset of cardiomyopathy, scoliosis, and first fractures; and pulmonary function among males 
with DMD from the population-based Muscular Dystrophy Surveillance, Tracking, and 
Research Network (MD STARnet).
2. Methods
2.1. Study population
Established in 2002 by the Centers for Disease Control and Prevention (CDC), the MD 
STARnet is a population-based surveillance program that retrospectively identified and 
prospectively followed cases with Duchenne and Becker muscular dystrophies (DBMD), 
who were born from January 1, 1982 through December 31, 2011, diagnosed by age 21 
years, and resided following diagnosis in one of six surveillance sites. Starting in 2004, 
Arizona, Colorado, Iowa, and western New York State began collecting data. Georgia joined 
the MD STARnet in 2006 and Hawaii in 2008. All cases were followed up for a minimum of 
1 year following identification. Arizona and Hawaii obtained institutional review board 
approval to ascertain cases with DBMD from multiple sources, such as hospital records, 
neuromuscular clinics, and birth defect surveillance programs. The remainder of sites 
amended existing state codes for public health surveillance of birth defects to make DBMD 
reportable conditions. Clinical data abstracted from medical records for each potential case 
were reviewed by a committee of neuromuscular physicians to assign a case definition of: 
definite, probable, possible, asymptomatic, or affected female [33]. ‘Definite’ cases had the 
documented clinical symptoms referable to a dystrophinopathy and direct support of the 
diagnosis by at least one of the following criteria: 1) DNA analysis demonstrating a 
dystrophin mutation; 2) muscle biopsy demonstrating abnormal dystrophin; or 3) elevated 
creatine kinase, X-linked pedigree, and an affected family member meeting one of the above 
2 criteria. ‘Probable’ cases lacked the DNA analysis data to meet the definition of definite 
cases. ‘Possible’ and ‘asymptomatic’ cases lacked further data required to meet criteria for 
definite case. More details of MDSTARnet surveillance methods have been published 
elsewhere [3,33,34].
Out of the 1054 cases identified by the MD STARnet, 918 males were assigned a definite or 
probable case definition. Age at onset of the first signs and symptoms was used to identify 
DMD cases, which was defined as onset of symptoms prior to the 6th birthday. Of the 918 
cases, 192 were excluded due to onset of first signs and symptoms documented in the 
medical record after the 6th birthday: a mobility issue including trouble rising/walking/
running/jumping, frequent falling/clumsy, Gower sign, gross motor delay, muscle weakness, 
or abnormal gait, which were used as a proxy for Becker muscular dystrophy. The final 
analytic dataset included 726 cases from 660 families. Among patients treated with steroid 
in our analytic sample, only those who had been treated for 6 or more months before 
developing a given outcome or before being right censored were considered for further 
analysis. Therefore, the analytical sample sizes varied from 481 to 666 cases for four clinical 
outcomes examined: age at loss of ambulation and ages at onset of cardiomyopathy, 
scoliosis, and first fractures (Table 1); data for 255 cases were available for pulmonary 
function analysis.
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2.2. Clinical outcomes
Age at loss of ambulation was defined as the age in years at which ‘ambulation ceased’ or 
‘fulltime wheel chair use’ was identified as first documented in medical records available for 
abstraction.
Age at cardiomyopathy onset was defined using standard measures of a diagnosis of 
cardiomyopathy [14,35–38]: a shortening fraction (SF) < 28%, an ejection fraction (EF) < 
55% if SF was not available, or a calculated SF < 28% based on M-Mode data of left 
ventricular end diastolic and end systolic dimensions when both SF and EF were not 
available.
Age at first diagnosis of scoliosis was defined as the age in years at the first report of spinal 
curvature >30° as measured by lumbar X-rays in medical records available for abstraction, 
or age in years of the first documented scoliosis surgery when X-ray records were 
unavailable.
Age at first fracture was defined as the age in years of the first fracture, regardless of site, 
experienced by a DMD case. The fracture sites recorded in our data and ordered by 
diminishing frequency were femur, tibia/fibula, humerus, spine, ankle, arm, leg, foot, 
clavicle, and wrist.
Forced vital capacity (FVC) values in liters (L) that met pulmonary function test (PFT) 
quality according to the American Thoracic Society (ATS)/European Respiratory Society 
2005 guidelines: ‘ATS criteria’, ‘good quality/effort’, or ‘repeatable’ (at least 3 FVCs: 2 
largest within 0.15 L; if FVC < 1.00 L, then within 0.10L) were used for analysis. Unlike the 
other four clinical outcomes examined, we extracted repeated FVC values, where available, 
and applied a different method for analysis as explained in the following section.
2.3. Classification of DMD cases by timing of corticosteroid initiation
Cases were classified into three treatment groups according to the use of corticosteroid 
treatment and the timing of treatment initiation. Cases without documentation of being 
prescribed corticosteroids were assigned to the corticosteroid naïve group; cases that 
initiated corticosteroid treatment (deflazacort, prednisone, or prednisolone) before or at 5 
years of age were assigned to the early childhood treatment group; and cases that initiated 
treatment after age 5 years were assigned to the late childhood treatment group. We set the 
minimum duration for treatment as a 6-month interval at any time prior to the occurrence of 
a clinical outcome examined (age at loss of ambulation; ages at onset of cardiomyopathy, 
scoliosis, and first fracture). Setting treatment duration at 6 months or more allowed 
assessment of the effect of longer-term corticosteroid treatment, which was the focus of this 
investigation. Because of the repeated outcomes used for the PFT analysis, cases with a 
minimum duration of 6 months of corticosteroid treatment prior to the initiation of the first 
PFT were included in our analyses.
2.4. Statistical analysis
For the onset of loss of ambulation, cardiomyopathy, scoliosis, or first fracture, we used 
Kaplan–Meier (KM) estimates to describe overall time to event and estimate the median age 
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(95% confidence interval, CI) at onset of each event by treatment group. We used Cox 
proportional hazard models to estimate associations between the age at clinical outcome and 
each treatment group (naïve, early childhood, and late childhood). For cases that did not 
show loss of ambulation, cardiomyopathy, or scoliosis by the end of the study period, we 
calculated two different right censored ages: age at their last recorded clinical test and age at 
last clinic visit. These analyses permitted us to examine the impact of right censoring on the 
results of cases who were followed but were never prescribed the relevant clinical test during 
the study period. Because a fracture was recorded when it occurred, cases without fractures 
were right censored only at the age of their last clinic visit. Analyses were repeated for each 
type of right censored age defined. We detected hazard rate differences for each pair of 
treatment groups (early vs naïve, early vs late, late vs naïve) using the Wald test. To account 
for possible outcome correlations among siblings, we used a robust sandwich estimator to 
estimate the covariance matrix [39]. Because cases who received treatment at an earlier age 
were likely to have an earlier age at onset of first signs or symptoms, disease severity may 
have differed among the treatment groups (e.g., overall, for the more severe cases in the 
early treatment group, the mean age at onset of first signs and symptoms for naïve, early, and 
late childhood treatment groups were 2.5, 2.1, and 2.7 years respectively), which may 
confound the associations estimated. Thus, we adjusted for age at onset of first sign or 
symptoms in all analyses as a continuous variable as a proxy for disease severity. Because of 
the potential for longer treatment duration among cases who started early compared to those 
who started late and the potential impact of treatment duration on clinical outcomes, we 
tested the difference in treatment duration among the early and late childhood treatment 
groups prior to applying Cox regression analysis. Also, in the Cox regression model for the 
analysis of the onset of cardiomyopathy, any use of cardiac medications prior to 
cardiomyopathy onset was included in the models and adjusted as a dummy variable. The 
names of medications (110 in total) used to treat cardiomyopathy were obtained from the 
American Heart Association and were matched to medications recorded in the surveillance 
database. We excluded reports of antiplatelet agents, anticoagulants, and statins [40].
Lastly, a linear regression was applied to estimate the expected difference of absolute FVC 
values between each pair of treatment groups examined, adjusting for age in years at each 
PFT along with age in years at onset of symptoms and signs. Because cases had repeated 
FVC values over time, the correlations among the repeated measurements were considered 
using a generalized estimating equation with a first-order autoregressive covariance 
structure. All analyses were done in SAS version 9.3 (SAS Institute, Cary, NC). In all 
analyses we considered for multiple testing using the Bonferroni correction; P-value ≤ 0.02 
≈ 0.05/3 was only treated statistically significant. We also conducted sensitivity analyses for 
all outcomes by excluding younger siblings from each family to examine the impact that the 
presence of an older affected sibling may have had on treatment initiation in younger 
siblings.
3. Results
Of the 726 cases in our analyses, 182 (25.1%) were abstracted from Georgia, followed by 
Arizona (23.8%), Colorado (21.1%), western NY (14.2%), Iowa (13.6%), and Hawaii 
(2.2%). By race/ethnicity, we had 437 (60.2%) cases who were non-Hispanic white, 148 
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(20.4%) Hispanic cases, 87 (12.0%) other race/ethnicity, and 54 (7.4%) with race/ethnicity 
missing. By corticosteroid treatment and timing of treatment initiation, 343 (47.3%, 301 
definite and 42 probable) cases were corticosteroid treatment naïve, 67 (9.2%, 66 definite 
and 1 probable) initiated treatment in early childhood, and 316 (43.5%, 296 definite and 20 
probable) initiated treatment in late childhood. Compared to cases in the late childhood 
treatment group, on average, those in the early childhood treatment group began treatment 
3.4 years earlier (age 4.2 vs 7.6 years, p < 0.001). The mean duration of corticosteroid 
treatment prior to each clinical outcome examined ranged from 5.9 to 6.4 years. For all 
outcomes, no statistical difference in treatment duration was found between the early and 
late childhood treatment groups (all p > 0.05, t-test) prior to the occurrence of any clinical 
outcome (data not shown).
When the right-censoring age was set at the last available clinical test record, the median age 
at which cases had a 50% chance of being ambulatory was estimated at 11.1 years for those 
who were treatment naïve, 13.2 years for those in the early childhood treatment group, and 
12.5 years for those in the late childhood treatment group (Table 1). For cardiomyopathy and 
scoliosis, the median ages free from each outcome were the greatest for cases in the late 
childhood treatment and naïve group (18.0 and 15.2 years respectively). When the right-
censoring age was set at the last clinic visit, as expected, the sample size was larger and the 
corresponding median ages tended to be slightly older for each treatment group due to the 
later time at which the cases were censored (Table 1). The median age free from the first 
fracture was estimated as the highest (19.6 years) in the late childhood treatment group. 
Overall survival rates by treatment group are presented in KM curves in Fig. 1.
In the Cox regression models adjusted for age at onset of first signs or symptoms (and 
cardiac medication use for the analysis of cardiomyopathy onset), the risk of 
cardiomyopathy and first fracture onset was significantly higher for cases in the early 
childhood treatment group compared to either those in the treatment naïve or the late 
childhood treatment groups (Table 2). When right censoring cases at last available clinical 
test record, the risk of cardiomyopathy onset among cases in the early childhood treatment 
group was 1.9 times as high as (95% CI = 1.1–3.2, P = 0.02) the risk for those in the 
treatment naïve group and 2.0 times as high as (95% CI = 1.2–3.4, P = 0.01) the risk for 
those in the late childhood treatment group. The hazard ratios (HRs) were comparable when 
the analyses were repeated using age at the last clinic visit for right censoring. Also, the risk 
for first fracture among cases in the early childhood treatment group was 2.6 times as high 
as (95% CI = 1.6–4.2, P < 0.01) the risk for those in the treatment naïve group and 2.3 times 
as high as (95% CI = 1.4–3.7, P < 0.01) the risk for those in the late childhood treatment 
group. No significant differences were observed between the late childhood treatment group 
and the treatment naïve group for onset of cardiomyopathy and first fracture. For loss of 
ambulation or onset of scoliosis, no significant associations were observed for the pairwise 
comparisons between treatment groups when right censoring cases at either age at last 
available clinic test record or age at last clinic visit.
Among the 726 cases analyzed, PFTs met the inclusion criteria in 255 (35.1%) cases with a 
total collection of 1030 absolute FVC values. Adjusting for age at onset of first sign or 
symptoms and age at each test in the linear regression model, the expected FVC value for 
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cases in the early childhood treatment were 0.39 L lower (P < 0.01) than the values for those 
in the late childhood treatment group (Table 3). No significant difference was observed for 
other pairs of groups (P > 0.02). For all analyses conducted, removal of younger siblings did 
not appreciably change the estimates observed from inclusion of all eligible cases in the 
analyses (data not shown).
4. Discussion
By analyzing the longitudinal, population-based data from the MD STARnet, we observed 
that DMD cases who initiated corticosteroid treatment early (age ≤5 years) were more likely 
to have earlier onsets of cardiomyopathy and first fracture compared with those who 
initiated treatment in late childhood (age >5 years) or those who were treatment naïve. 
Patients who initiated treatment early also showed overall decreased respiratory function 
compared with the patients in the late childhood treatment group. For all outcomes 
examined, no statistically significant differences were observed between the treatment naïve 
group and late childhood groups.
A recent 14-year follow-up study of 8 boys who received early childhood treatment with 
corticosteroids (ages 2–4 years) reported that such treatment preserved pulmonary and 
cardiac function for 4 of the boys [9]. Of these 4 boys with preserved pulmonary and cardiac 
function, FVCs were also normal in 2 boys and mildly reduced in the other 2 boys; left 
ventricular EF was normal in 3 boys at their last follow-up (ages 16–18 years). By 
comparison, the 4 boys in the study without preserved pulmonary and cardiac function were 
reported to have lost ambulation or the ability to rise before age 10 years. Other 
investigations have indicated the potential benefits of corticosteroid treatment on cardiac 
function [7,14,17], but not consistently [41,42]. Using MD STARnet data, Barber et al. 
reported a delayed onset of cardiomyopathy among corticosteroid users, compared to the 
naïve group [14]. This finding appears to be inconsistent with the present study. A key 
difference is that in the present study the corticosteroid treated patients were separated into 
early treated and late treated; whereas these two groups were combined into a single 
treatment group in Barber et al. Of note, in the present study the risk of cardiomyopathy 
onset among those aged about 12 to 18 years was estimated lower in the late treatment group 
compared to the treatment naïve group, but this difference did not reach statistical 
significance in the period of the study. Inverse associations of corticosteroid treatment with 
fractures [6,8] and scoliosis [8,43] in DMD, relative to untreated boys, have been reported 
previously; however, in these efficacy studies, the start of corticosteroid was either unknown 
or it was later than age 6 years. It is possible that the lower FVC in early treated cases 
reflects greater total body growth suppression from longer and/or early steroid treatment. 
However, we do not have enough data to compare growth among the cases who were 
treatment naïve vs the other treated groups.
In this study we simply assessed the potentially adverse relation between morbidity and 
timing of corticosteroid treatment initiation. Because this is an observational study, we 
cannot conclude that early treatment resulted in poorer clinical symptoms. A randomized 
clinical trial would be the definitive method to address this issue; however, given the 
progressive nature of DMD, we can anticipate that the efficacy of early treatment may alter 
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the natural history to the point that it becomes comparable to the progression observed 
among those with a presumed less severe phenotype (i.e., late childhood treatment or 
treatment naïve groups).
The relatively severe phenotype or rapid disease progression, such as the one possibly 
present in the early childhood treatment group, may lead to a higher risk of developing 
cardiomyopathy, suffering fractures, or decreasing pulmonary function compared to cases 
without this phenotype. To account for this possibility, we controlled for age at onset of first 
signs and symptoms as a proxy for disease severity across treatment groups. Interestingly, 
we observed no statistical difference of clinical symptoms examined between the cases in 
the treatment naïve and late childhood treatment groups. It is possible that the comparable 
disease severity in the two groups with corticosteroid treatment (age 2.1 and 2.7 years for 
age at onset of first signs and symptoms for early and late treated groups, respectively) was 
not altered by the treatment in one group, or our data did not have enough statistical power 
to detect such a difference. However, lack of statistical significance does not mean lack of 
clinical significance.
To our knowledge, this is the first large-scale study examining the associations between 
corticosteroid treatment and timing of initiation with several clinical outcomes in the same 
study population. These clinical outcomes often have been included in DMD studies related 
to the efficacy of corticosteroid treatment, but have been reported separately. Variations of 
study population and study designs can hinder the synthesis of findings regarding the effect 
of corticosteroid treatment on clinical outcomes. Although the evaluation of multiple clinical 
outcomes in one study is desirable, it requires extensive clinical data collection with an 
extended follow-up period in a large cohort, such as that available in the MD STARnet. 
Further, in previous related studies, DMD patients were followed mostly to the mid- or late-
teenage years [7,9,11,12,21], whereas the MD STARnet followed some cases to their late-
twenties.
Even with this data resource, our study has several limitations. First, our data were collected 
from medical record abstraction, which does not involve assessment at fixed intervals for all 
cases. Thus, not all cases were evaluated for each clinical outcome using formal clinical 
testing, nor were those tested evaluated at regular, predefined intervals. As a result, detection 
bias may have been introduced. For example, the cases who started corticosteroids earlier 
may have had more frequent clinician contact than those who started later; therefore, their 
cardiomyopathy possibly could be diagnosed at an earlier age. Second, we did not separate 
drug type, dosage regimen, or dosing interval for the early and late childhood treatment 
groups, which may have impacted our findings regarding side-effects [44] because it further 
reduced sample size in the treated group due to lack of data. Overall, of the 2750 
corticosteroid treatment episodes documented for the cases in MD STARnet, by drug type, 
66% were treated with prednisone, 29% with deflazacort, and 5% were missing. By dosing 
interval, 74% had the treatment daily, 16% every other day, 7% two days/week, and 3% 
other intervals. Since the MD STARnet abstractors only recorded the total dose (mg), not the 
dose per body weight (e.g., mg/kg), dosage information were not provided. Third, our cases 
were limited to those with age at onset of first signs or symptoms before age 6 years to 
exclude Becker muscular dystrophy cases. Sometimes, age at loss of ambulation is used to 
Kim et al. Page 8
Neuromuscul Disord. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
differentiate between Becker and Duchenne cases, but the age of loss of ambulation can be 
modified by treatment and management. A standard age cutoff for this differentiation is not 
widely accepted, especially when individuals receive corticosteroids. Despite use of age at 
first onset of signs or symptoms to exclude Becker-like dystrophinopathy, our data may have 
some individuals with the Becker phenotype in the untreated and late groups, because there 
were individuals still ambulating after age 15 years. Fourth, as the data came from medical 
record abstraction, the method of right-censoring age (i.e., age at last available clinical test 
or age at last clinic visit) may produce systemic bias. The former censoring scheme excludes 
cases that did not have documented clinical evaluation of the outcome during the study. The 
absence of a clinical test may or may not indicate normal function with regard to the clinical 
outcomes examined due to young age, at which a clinical test may not be warranted, clinical 
symptoms that are not strong enough to prompt a clinical test, or the absence of clinical 
symptoms upon evaluation by the neuromuscular physician. Alternatively, when censoring at 
the last clinic visit, we cannot assume normal function for the clinical outcomes examined at 
this visit without a clinical test, and perhaps the last clinic visit occurred in a specialty clinic 
in which only a single outcome was assessed. Overall, our results were similar for both right 
censoring approaches used. Fifth, although our data collection was longitudinal, the median 
follow-up years might not have been long enough; median follow-up age in years [range] 
were 13 [1–29], 11 [3–28], 15 [6–31] for treatment naïve, early, and late childhood treatment 
groups, respectively. It is possible that we did not precisely capture the clinical patterns of 
cases at their later ages. Sixth, the small sample size in the early childhood treatment group 
(n ≤ 60) relative to the other groups provides low statistical power for the detection of any 
statistical difference of clinical function between this and the other groups. Seventh, it is 
possible that we have underestimated the age at loss of ambulation since ambulation can be 
lost abruptly after a fall and fracture that can end walking much earlier. Lastly, our study 
lacked genetic test data for some cases; it has been suggested that genetic markers of disease 
progress such as Osteopontin or LTBP4 genotype may affect the progression of some of the 
clinical outcomes examined [45,46].
In conclusion, we found evidence that DMD cases in the MD STARnet who initiated 
corticosteroid treatment during early childhood were likely to have a higher risk of 
developing earlier onset cardiomyopathy, suffering a fracture, and decreased respiratory 
function, compared to cases who initiated treatment in late childhood or were treatment 
naïve. Although there is increasing interest in the effects of early childhood treatment with 
corticosteroids on clinical outcomes [47] and apparently more clinicians are prescribing 
corticosteroid treatment earlier, the available data to comprehensively evaluate such effects 
in extended follow-up periods are scant. Because corticosteroids remain a treatment of 
choice for DMD, continued, careful assessments of the timing of initiating of this treatment 
are needed. Our study can be a valuable reference for these future studies.
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Fig. 1. 
Kaplan–Meier curve for loss of ambulation, onset of cardiomyopathy, scoliosis, and fracture 
by timing of corticosteroid treatment initiation. The Y-axis value represents the probability 
of ambulation, and probability free from onset of cardiomyopathy, scoliosis, or fracture 
accordingly (Muscular Dystrophy Surveillance Tracking, and Research Network, 1982–
2011).
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